Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PanaKare Plus is a **veterinary pancreatic enzyme replacement product** developed and marketed by Neogen for use in dogs and cats with **exocrine pancreatic insufficiency** and related maldigestion. It is a **porcine-derived pancreatic enzyme concentrate** containing **lipase, protease, and amylase**, and is fortified with the fat-soluble vitamins **A, D3, and E**. Its mechanism is digestive enzyme replacement: when given orally before meals, it supplements deficient endogenous pancreatic enzymes in the gastrointestinal tract to improve digestion of fats, proteins, and carbohydrates. The product is supplied in **powder and tablet** formulations and is marketed as an **unapproved animal drug**, meaning FDA has not found it safe and effective and has not approved its labeling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PanaKare Plus.